|
|
|
|
Vol. 56, Issue 1, 185-195, July 1999
Departments of Biochemistry (S.P., N.W., S.E., F.H.), Pharmacology
(L.Y., J.B., F.H., S.H.), and Medicinal Chemistry (F.H., H.B.),
Merck Sharp and Dohme Research Laboratories, Neuroscience Research
Centre, Harlow, Essex, United Kingdom
K-252b, a member of the staurosporine family of protein kinase
inhibitors, selectively potentiates the activation of the nerve growth
factor receptor, TrkA, by a nonpreferred ligand, neurotrophin-3 (NT-3),
in a variety of cell types. At higher (micromolar) concentrations of
K-252b, an inhibitory effect occurs because of the inhibitory action of
K-252b on the Trk kinase. By examining analogs of K-252b, we
identified the compound L-753,000 (NB-506), which potentiates the
action of NT-3 on TrkA but is devoid of the inhibitory action of
K-252b. L-753,000 was effective at nanomolar concentrations in a
Chinese hamster ovary cell line that expressed TrkA but was devoid of
p75, the low-affinity neurotrophin receptor. L-753,000 also potentiated
the activation of mitogen-activating protein kinase signaling
(downstream from Trk activation) by NT-3 in this cell line. Although
L-753,000, like K-252b, had a negligible effect in the absence of NT-3,
the compound was found to potentiate NT-3-induced survival in both rat
and chick primary cultures of dissociated dorsal root ganglia (DRG) and
on neurite outgrowth of chick DRG explants. Unlike K-252b, which at
micromolar concentrations inhibits the survival response of NT-3 in
dissociated rat DRG, L-753,000 continued to potentiate the actions of
NT-3 up to a concentration of 10 µM. Furthermore, the compound,
unlike K-252b, did not inhibit an unrelated protein kinase, protein
kinase C, at concentrations up to 10 µM. Because L-753,000
selectively potentiates the NT-3-induced stimulation of TrkA without
inhibiting Trks and other protein kinases, it represents a novel class
of selective modifiers of neurotrophin actions.
This article has been cited by other articles:
![]() |
M. A. Lewis, L. Hunihan, D. Franco, B. Robertson, J. Palmer, D. R. St. Laurent, B. N. Balasubramanian, Y. Li, and R. S. Westphal Identification and Characterization of Compounds That Potentiate NT-3-Mediated Trk Receptor Activity Mol. Pharmacol., April 1, 2006; 69(4): 1396 - 1404. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Solier, A. Lansiaux, E. Logette, J. Wu, J. Soret, J. Tazi, C. Bailly, L. Desoche, E. Solary, and L. Corcos Topoisomerase I and II Inhibitors Control Caspase-2 Pre-Messenger RNA Splicing in Human Cells Mol. Cancer Res., January 1, 2004; 2(1): 53 - 61. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Ramm, Y. Alexandrov, A. Cholewinski, Y. Cybuch, R. Nadon, and B. J. Soltys Original Papers: Automated Screening of Neurite Outgrowth J Biomol Screen, February 1, 2003; 8(1): 7 - 18. [Abstract] [PDF] |
||||
![]() |
Y. Urasaki, G. Laco, Y. Takebayashi, C. Bailly, G. Kohlhagen, and Y. Pommier Use of Camptothecin-resistant Mammalian Cell Lines to Evaluate the Role of Topoisomerase I in the Antiproliferative Activity of the Indolocarbazole, NB-506, and Its Topoisomerase I Binding Site Cancer Res., January 1, 2001; 61(2): 504 - 508. [Abstract] [Full Text] |
||||